Skip to main content
Adaptimmune Therapeutics PLC logo

Adaptimmune Therapeutics PLC — Investor Relations & Filings

Ticker · ADAP ISIN · US00653A1079 LEI · 549300UUNWK8TRT5EW12 US Manufacturing
Open in API
Filings indexed 807 across all filing types
Latest filing 2018-09-04 Regulatory Filings
Country GB United Kingdom
Listing US ADAP

About Adaptimmune Therapeutics PLC

https://www.adaptimmune.com/

Adaptimmune Therapeutics is a commercial-stage biopharmaceutical company specializing in the development of novel T-cell receptor (TCR) T-cell therapies for cancer. The company utilizes a proprietary platform to engineer a patient's own T-cells to recognize and fight solid tumors. Its first FDA-approved therapy, Tecelra (afami-cel), is a treatment for advanced synovial sarcoma. Adaptimmune is advancing a robust pipeline of cell therapies, including preclinical programs targeting PRAME and CD70, as well as an allogeneic platform. The company's mission is to deliver transformative, potentially single-infusion treatments to reshape cancer care for patients with difficult-to-treat solid tumors.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2018
Regulatory Filings
2018-09-04 English
4
Director's Dealing
2018-09-01 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text indicates it reports "Other Events" related to a press release about safety data from a clinical study dose cohort. The document is short (3824 characters) and includes a press release as an exhibit. There is no detailed financial data or comprehensive report content. The document is an announcement of an event and a press release, not a full financial report or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2018-08-15 English
4
Director's Dealing
2018-08-07 English
10-Q
Interim / Quarterly Report Q2 2018
2018-08-02 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 2, 2018, reporting the results of operations and financial conditions for the second quarter ended June 30, 2018. It specifically states that the company issued a press release announcing its financial results for Q2 2018 and a business update, and the press release is attached as Exhibit 99.1. The document itself is a current report (8-K) that announces the earnings release but does not contain the full financial statements or detailed financial analysis. The length is 3649 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, initial announcements of quarterly financial results (key highlights only) are classified as Earnings Release (ER). Since this is a Form 8-K announcing the earnings release and attaching the press release, it fits best under Earnings Release (ER).
2018-08-02 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.